Skip to content

Clovis Oncology, Inc.

CIK 0001466301

← back to feed
Revenue (TTM)
$134.97M
−5.1% YoY Q3 Nov 2022
Net Income (TTM)
−$254.93M
+4.5% YoY Q3 Nov 2022
EPS Diluted (TTM)
−$1.89
+10.7% YoY Q3 Nov 2022
Gross Margin
80.3%
Q3 Nov 2022
Operating Margin
-156.7%
Q3 Nov 2022
Net Margin
-188.9%
Q3 Nov 2022
Free Cash Flow (TTM)
−$302.78M
Q3 Nov 2022
Cash
$58.32M
Q3 Nov 2022
Total Debt
$876.12M
Q3 Nov 2022
Shares Outstanding
144.96M sh
Q3 Nov 2022

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings